Products
Our formulations provide the potential to deliver CNS-based pharma therapeutics across the Blood Brain Barrier to increase drug efficacy and benefit to maximize patient outcomes.

NEO100 is a highly purified form of the natural compound Perillyl Alcohol (POH). Research evidence has shown that POH can interfere with the replication of dividing cells such as seen in cancer. POH has shown antitumor activity against a range of cancer types including pancreatic, lung, colon, and liver cancers in laboratory and animal studies and an inhaled form of POH has shown preliminary evidence of safety and effectiveness in patients with recurrent gliomas.
NEO100 is being tested as an intranasal delivery molecule for the treatment of Grade IV gliomas. Grade IV gliomas are among the most aggressive and deadly forms of brain cancers, and patients with this form of cancer face a grim prognosis. Only a quarter of newly diagnosed Glioblastoma patients survive for 24 months, and fewer than 10 percent of patients survive more than 5 years.
Globally, approximately 300,000 men and women are diagnosed with cancer of the brain and nervous system every year, and more than 240,000 deaths are caused by the disease. It is also one of the primary cancers that affect children and young adults.
NEO212 is a chemical conjugation of the DNA alkylating agent Temozolomide (TMZ) with our highly purified formulation of Perillyl Alcohol (POH). TMZ continues to be the gold standard in the treatment of anaplastic astrocytoma, and glioblastoma multiforme cancers. It works by slowing or stopping the growth of cancer cells in your body. Recent studies have shown the 1-year and 2-year survival rates were 37.8% and 10.4% with radiation plus temozolomide, versus 22.2% and 2.8% with radiation therapy alone.
The NEO212 formulation was designed to see if increased efficacy TMZ could be achieved through intranasal delivery within the patented wrapper technology.
The primary target for Temozolomide (TMZ) is glioblastoma multiforme. It is estimated that close to 25, 000 people in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord this year. Brain tumors account for 85% to 90% of all primary central nervous system (CNS) tumors. Since treatment using TMZ is generally through a series of oral dosages or by intravenous infusion, its effectiveness is inhibited by the need for uptake to occur through the intestinal or circulatory system. Primary side effects include bone marrow suppression, nausea, vomiting, constipation, loss of appetite, and more.
NEO212 hopes to improve efficacy while minimizing the side-effect issues currently associated with TMZ treatment.
